Open AccessPentraxin 3 might be better prognostic serum marker than IL-6, IL-10, and high-sensitivity C-reactive protein for major adverse cardiovascular events in patients with ST-elevation myocardial infarction after bare-metal stent implantation
Author(s) -
Farid Ljuca,
Bahrudin Hadžiefendić,
Elmir Jahić,
Nijaz Tihić,
Saša Lukić
Publication year - 2019
Publication title -
saudi medical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.437
H-Index - 51
eISSN - 1658-3175
pISSN - 0379-5284
DOI - 10.15537/smj.2019.12.24737
Subject(s) - medicine , conventional pci , percutaneous coronary intervention , cardiology , myocardial infarction , c reactive protein , ptx3 , troponin i , inflammation
To assess the prognostic value of pentraxin 3 (PTX3) in patients with ST-elevation myocardial infarction (STEMI) after bare-metal stent (BMS) implantation.